Project: Research project

Project Details


The first cases of pediatric AIDS in Miami were born in 1979. The first
diagnoses were made in 1982 and through September, 1985, 74 cases of
HTLV-III infection in infants and children have been identified in 60
households. The initial enrollment period was from March, 1983 until
October, 1984. Seventeen index cases and an equal number of matched
comparison cases and their respective households were enrolled and followed
longitudinally since enrollment. The follow-up rate on this group exceeded
90% in the current grant period. Diagnostic and laboratory parameters
including HTLV-III isolation and serologic procedures were established and
pediatric AIDS has been defined in this group. The mothers of
perinatally-infected index cases are themselves infected with HTLV-III and
have profound immune dysfunction and although clinically healthy at the
time of delivering an infected infant, a significant number of the mothers
subsequently develop AIDS. The mothers are persistently infected with the
virus and may give birth to multiply affected sibships. Of 20 infants born
to mothers after a previously identified pediatric AIDS index case, 65% of
the subsequent children are infected. In contrast to this high rate of
perinatal infection, there has been no evidence of casual infection noted
in households. The overall case fatality rate is 35%, although in certain
clinical syndromes such as lymphocytic interstitial pneumonitis, the rate
is only 14% suggesting that there may be distinct clinical outcomes perhaps
associated with different immune responses to the virus. It is proposed to
enroll all surviving index cases diagnosed before and after the initial
enrollment period and to follow a total of some 75 pediatric AIDS cases for
four more years to enlarge our data base and to extend the period of
follow-up. This will provide information on the late outcome of pediatric
AIDS, the possibility of HTLV-III transmission in households and an
evaluation of late outcome in HTLV-III virus-positive mothers. Virus
isolates will be characterized and antibody responses to HTLV-III will be
measured to evaluate the respective roles of viral variation, antibody
formation and clinical disease.
Effective start/end date9/30/838/31/91


  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health


  • Medicine(all)
  • Immunology and Microbiology(all)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.